@article{2b36ff97681b4a67a3a7597918f611ba,
title = "Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy",
author = "Barbara Muz and Feda Azab and Mark Fiala and Justin King and Daniel Kohnen and Fogler, {William E.} and Ted Smith and Magnani, {John L.} and Ravi Vij and Azab, {Abdel Kareem}",
note = "Funding Information: GMI-1271 and GMI-1359 antagonists were provided by GlycoMimetics Inc. (Rockville, MD). The study was supported partially by a research grant from GlycoMimetics, Inc. and by the award from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and the National Cancer Institute of the NIH (U54CA199092). The imaging studies were supported by NIH P50 CA094056 (Molecular Imaging Center) and NCI P30 CA091842 (Siteman Cancer Center Small Animal Cancer Imaging shared resource). The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH.",
year = "2019",
month = sep,
day = "1",
doi = "10.1038/s41408-019-0227-3",
language = "English (US)",
volume = "9",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "9",
}